Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies
Patricia Diaz‐Galvan, Scott A. Przybelski, Alicia Algeciras‐Schimnich, Daniel J. Figdore, Timothy G. Lesnick, Christopher G. Schwarz, Matthew L. Senjem, Jeffrey L. Gunter, Clifford R. Jack, Hoon‐Ki Min, Manoj Jain, Toji Miyagawa, Leah K. Forsberg, Julie A. Fields, Rodolfo Savica, Jonathan Graff‐Radford, Vijay K. Ramanan, David T. Jones, Hugo Botha, Erik K. St. Louis, David S. Knopman, Neill R. Graff‐Radford, Tanis J. Ferman, Ronald C. Petersen, Val J. Lowe, Bradley F. Boeve, Kejal Kantarci
Abstract
INTRODUCTION: Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease. METHODS: The cohort included patients with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment with Lewy bodies (MCI-LB), or DLB, with a concurrent blood draw and PET scans. RESULTS: Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. Abnormal levels of plasma phosphorylated tau (p-tau)-181 and neurofilament light (NfL) were found at the DLB stage. Plasma p-tau-181 showed the highest accuracy in detecting abnormal amyloid and tau PET in patients with DLB. DISCUSSION: The range of AD co-pathology can be detected with plasma biomarkers in the DLB continuum, particularly with plasma p-tau-181 and GFAP.